Helomics® Corporation, a privately-held, personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services, announced today that the National Acquisition Center of the Department of Veterans Affairs has awarded the company a Federal Supply Schedule (FSS) Contract V797D-506041, effective June 1, 2016 through May 31, 2021. The awarding of this contract will provide all government facilities, including those operated by the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD), easy access to Helomics’ ChemoFx® tumor profiling test. read more
The next generation in Personalized Healthcare™
Personalized healthcare should be comprehensive, precise, predictive, but most importantly, personal.
We believe that each patient is unique, and their cancer treatment should be too.
Helomics' ongoing array of multiple products and technologies provide unique clinical value through a Comprehensive Tumor Profile.
peer reviewed publications and
abstracts on ChemoFx
gynecologic cancer specimens received for ChemoFx testing
physicians have sent for ChemoFx testing
unique sets of gynecologic cancer cell specimens in our Biorepository